Clinical Trial Update: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab [Phase 3]

View source ↗

Summary

A Phase 3 trial in children with juvenile psoriatic arthritis compares subcutaneous risankizumab to adalimumab, evaluating adverse events, changes in disease ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Psoriatic Arthritis

Drugs mentioned

• Humira (adalimumab)
• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: AbbVie | Conditions: Juvenile Psoriatic Arthritis | Phase 3 | Status: RECRUITING